No connection

Search Results

ADTX vs INM

ADTX
Aditxt, Inc.
BEARISH
Price
$1.82
Market Cap
$0.4M
Sector
Healthcare
AI Confidence
95%
INM
InMed Pharmaceuticals Inc.
BEARISH
Price
$0.72
Market Cap
$2.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ADTX
--
INM
--
Forward P/E
ADTX
-0.16
INM
-0.11
P/B Ratio
ADTX
-0.01
INM
0.21
P/S Ratio
ADTX
67.96
INM
0.53
EV/EBITDA
ADTX
-0.22
INM
0.57

Profitability

Gross Margin
ADTX
0.0%
INM
29.73%
Operating Margin
ADTX
-419870.0%
INM
-258.57%
Profit Margin
ADTX
0.0%
INM
-170.07%
ROE
ADTX
--
INM
-97.2%
ROA
ADTX
-61.7%
INM
-49.77%

Growth

Revenue Growth
ADTX
-89.1%
INM
-26.2%
Earnings Growth
ADTX
--
INM
--

Financial Health

Debt/Equity
ADTX
--
INM
0.06
Current Ratio
ADTX
0.02
INM
5.94
Quick Ratio
ADTX
0.02
INM
4.85

Dividends

Dividend Yield
ADTX
--
INM
--
Payout Ratio
ADTX
0.0%
INM
0.0%

AI Verdict

ADTX BEARISH

ADTX exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of an Altman Z-Score, which raises significant bankruptcy risk. The company is unprofitable with a negative ROA of -61.70%, a gross margin of 0.00%, and a staggering -419,870.30% operating margin. Revenue has collapsed by 89.10% YoY, and the stock has declined 100% over the past five years. Despite a low price of $1.82, the valuation metrics are nonsensical (e.g., Price/Sales of 67.96, negative P/E), suggesting extreme overvaluation or data failure. The absence of any analyst coverage and negative insider activity further confirm a lack of institutional confidence.

Strengths
Minimal market cap may offer speculative appeal for high-risk investors
Recent quarter showed a slight Q/Q EPS improvement (+6.9%)
One quarter beat earnings estimate (1/4), indicating potential for volatility in results
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational efficiency
Negative ROA (-61.70%) and operating margin (-419,870.30%) signal severe profitability collapse
Revenue declined 89.10% YoY, with inconsistent and erratic earnings surprises (avg -96.38%)
INM BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.

Strengths
Very low Debt/Equity ratio (0.06) indicating minimal long-term debt burden
Strong short-term liquidity with a Current Ratio of 5.94
Positive Gross Margin (29.73%) suggesting the core product has some inherent value
Risks
Critical financial health as evidenced by a 1/9 Piotroski F-Score
Severe operational inefficiency with an Operating Margin of -258.57%
Negative revenue growth (-26.20% YoY) indicating shrinking market share or demand

Compare Another Pair

ADTX vs INM: Head-to-Head Comparison

This page compares Aditxt, Inc. (ADTX) and InMed Pharmaceuticals Inc. (INM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile